Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancreatectomy with nituzumab plus gemcitabine and albumin-bound paclitaxel in locally advanced pancreatic cancer
ChiCTR2400084464Phase 3Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nimotuzumab, gemcitabine and nab-paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Radical resection rate (R0), Conversion rate and 2 more. Started May 2024; status: recruiting.
02
Drugs
nimotuzumabgemcitabinenab-paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400084464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084464.